27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target

MLA

T.A. Yap, et al. “27O First-in-Class First-in-Human Phase I Trial of RBN-2397 in Patients with Advanced Solid Tumors Validates PARP7 as a Novel Anticancer Therapeutic Target.” ESMO Open, vol. 8, Mar. 2023, p. 100993. EBSCOhost, https://doi.org/10.1016/j.esmoop.2023.100993.

APA

T.A. Yap, A. Cervantes, G. Falchook, M. Patel, D. Juric, S.N. Waqar, E. Schenk, G. Shapiro, V. Boni, C.A. Perez, B. Burtness, Y. Najjar, F.E. Racca, K.I. Rojas Laimito, K. Kuplast-Barr, K. McEachern, M. Samant, V. Bozón, S. Parasuraman, & M.L. Johnson. (2023). 27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target. ESMO Open, 8, 100993. https://doi.org/10.1016/j.esmoop.2023.100993

Chicago

T.A. Yap, A. Cervantes, G. Falchook, M. Patel, D. Juric, S.N. Waqar, E. Schenk, et al. 2023. “27O First-in-Class First-in-Human Phase I Trial of RBN-2397 in Patients with Advanced Solid Tumors Validates PARP7 as a Novel Anticancer Therapeutic Target.” ESMO Open 8 (March): 100993. doi:10.1016/j.esmoop.2023.100993.